| Oncomine™ Dx Target TestLife Technologies CorporationMultiple tissue-associated protein/tumour marker IVD, reagent | A32441 | Life Technologies Corporation | Multiple tissue-associated protein/tumour marker IVD, reagent |
| oncoReveal CDxPillar Biosciences, Inc.Colorectal cancer genotyping IVD, kit, nucleic acid technique (NAT) | HDA-LC-2001-48 | Pillar Biosciences, Inc. | Colorectal cancer genotyping IVD, kit, nucleic acid technique (NAT) |
| oncoReveal CDx Box 3Pillar Biosciences, Inc.Colorectal cancer genotyping IVD, kit, nucleic acid technique (NAT) | HDA-LC-2001-48-3 | Pillar Biosciences, Inc. | Colorectal cancer genotyping IVD, kit, nucleic acid technique (NAT) |
| PGDx elio™ plasma focus DxPersonal Genome Diagnostics Inc.Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) | B01103102 | Personal Genome Diagnostics Inc. | Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) |
| PGDx elio™ serverPersonal Genome Diagnostics Inc.Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) | B-01-20800 | Personal Genome Diagnostics Inc. | Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) |
| PGDx elio™ serverPersonal Genome Diagnostics Inc.Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) | B-01-30800 | Personal Genome Diagnostics Inc. | Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) |
| PGDx elio™ serverPersonal Genome Diagnostics Inc.Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) | B-01-40800 | Personal Genome Diagnostics Inc. | Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) |
| Prosigna Breast Cancer Prognostic Gene Signature AssayNanostring Technologies, Inc.Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) | PROSIGNA-001 | Nanostring Technologies, Inc. | Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) |
| Prosigna Breast Cancer Prognostic Gene Signature AssayNanostring Technologies, Inc.Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) | PROSIGNA-002 | Nanostring Technologies, Inc. | Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) |
| Prosigna Breast Cancer Prognostic Gene Signature AssayNanostring Technologies, Inc.Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) | PROSIGNA-003 | Nanostring Technologies, Inc. | Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) |
| Prosigna Breast Cancer Prognostic Gene Signature AssayNanostring Technologies, Inc.Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) | PROSIGNA-010 | Nanostring Technologies, Inc. | Cancer-related multiple gene mutation/mRNA expression IVD, kit, nucleic acid technique (NAT) |
| QuantideX qPCR BCR-ABL IS KitAsuragen, Inc.Philadelphia chromosome/BCR-ABL mRNA expression IVD, kit, nucleic acid technique (NAT) | 49574 | Asuragen, Inc. | Philadelphia chromosome/BCR-ABL mRNA expression IVD, kit, nucleic acid technique (NAT) |
| RealTimeAbbott Molecular Inc.Isocitrate dehydrogenase 2 (IDH2) gene mutation IVD, kit, nucleic acid technique (NAT) | 08N82-090 | Abbott Molecular Inc. | Isocitrate dehydrogenase 2 (IDH2) gene mutation IVD, kit, nucleic acid technique (NAT) |
| SensID Idylla™ MSI FFPE Reference SetSensID GmbHExogenous DNA/RNA internal control IVD, kit | 2x2 | SensID GmbH | Exogenous DNA/RNA internal control IVD, kit |
| SensID Idylla™ MSI FFPE Reference SetSensID GmbHExogenous DNA/RNA internal control IVD, kit | 2x3 | SensID GmbH | Exogenous DNA/RNA internal control IVD, kit |
| therascreen® PDGFRA RGQ PCR KitQIAGEN GmbHGastrointestinal cancer genotyping IVD, kit, nucleic acid technique (NAT) | 1 | QIAGEN GmbH | Gastrointestinal cancer genotyping IVD, kit, nucleic acid technique (NAT) |
| TruSight™ Oncology DNA Control v2Illumina, Inc.Cancer-related multiple gene mutation profile IVD, control | 20090155 | Illumina, Inc. | Cancer-related multiple gene mutation profile IVD, control |
| TruSight™ Oncology RNA ControlIllumina, Inc.Cancer-related multiple gene mutation profile IVD, control | 20065042 | Illumina, Inc. | Cancer-related multiple gene mutation profile IVD, control |
| Xpert BCR-ABL 0%ISMmqciPhiladelphia chromosome/BCR-ABL transcript IVD, control | v.00 | Mmqci | Philadelphia chromosome/BCR-ABL transcript IVD, control |
| Xpert BCR-ABL IS Panel C130MmqciPhiladelphia chromosome/BCR-ABL transcript IVD, control | v.00 | Mmqci | Philadelphia chromosome/BCR-ABL transcript IVD, control |
| Xpert BCR-ABL UltraCepheidPhiladelphia chromosome/BCR-ABL mRNA expression IVD, kit, nucleic acid technique (NAT) | GXBCRABL-US-10 | Cepheid | Philadelphia chromosome/BCR-ABL mRNA expression IVD, kit, nucleic acid technique (NAT) |
| xTAG® Cystic Fibrosis (CFTR) 39 kit v2Luminex Molecular Diagnostics, IncCystic fibrosis IVD, kit, multiplex | I027C0231 | Luminex Molecular Diagnostics, Inc | Cystic fibrosis IVD, kit, multiplex |
| xTAG® Cystic Fibrosis (CFTR) 60 kit v2Luminex Molecular Diagnostics, IncCystic fibrosis IVD, kit, multiplex | I024C0181 | Luminex Molecular Diagnostics, Inc | Cystic fibrosis IVD, kit, multiplex |